New combo therapy shows promise for Hard-to-Treat blood cancers

NCT ID NCT02362035

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a combination of two drugs, acalabrutinib and pembrolizumab, in 161 people with various blood cancers such as lymphoma, leukemia, and multiple myeloma. The main goal was to check safety and side effects, while also seeing if the tumors shrank. The approach aims to control the disease rather than cure it, as ongoing treatment may be needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BURKITT LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Tucson, Arizona, 85704, United States

  • Research Site

    Los Angeles, California, 90095, United States

  • Research Site

    Denver, Colorado, 80218, United States

  • Research Site

    Washington D.C., District of Columbia, 20007, United States

  • Research Site

    Niles, Illinois, 60714, United States

  • Research Site

    Boston, Massachusetts, 2215, United States

  • Research Site

    Rochester, Minnesota, 55905-0001, United States

  • Research Site

    Omaha, Nebraska, 68198-7680, United States

  • Research Site

    Columbus, Ohio, 43210, United States

  • Research Site

    Greenville, South Carolina, 29605, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Dallas, Texas, 75246, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78217, United States

  • Research Site

    Tyler, Texas, 75702, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Roanoke, Virginia, 24014, United States

  • Research Site

    Vancouver, Washington, 98684, United States

  • Research Site

    Yakima, Washington, 98902, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.